Fig 5.

Graph illustrates diminishing quantitative G6PD activity (left y-axis) with increasing proportions of 1.0 mM CuCl-treated red blood cells (RBCs) with untreated RBCs (x-axis) and the proportion of qualitative tests (fluorescent spot test [FST], solid line and filled circles or CareStart G6PD [CSG], dashed line and × marks) positive for G6PD deficiency (right y-axis). As in heterozygous states of G6PD deficiency, only CuCl-treated RBCs experience the effects of CuCl inhibition of G6PD. Hollow circles indicate quantitative G6PD measures defining a mean (solid lateral line) within boxes of 95% confidence intervals in the observed range of values (T lines at either end of the boxes).